Latest News

Piramal Pharma Limited (PPL), a subsidiary of Piramal Enterprises Limited (“PEL”, NSE: PEL, BSE: 500302, 912460) today received INR 3523.40 Crores on closure of the transaction for 20% equity investment from CA Alchemy Investments (formerly known as CA Clover Intermediate II Investments), an affiliated entity of CAP V Mauritius Limited, an investment fund managed and advised by affiliated entities of The Carlyle Group Inc. (“Carlyle”). The transaction values the Pharma Business at an enterprise value (EV) of US$2,775 million with an upside component of up to US$360 million depending on the company’s FY21 performance. This transaction is one of the largest private equity deals in the Indian pharmaceutical sector. It provides PPL growth capital that enables it to invest in accelerated business growth through both organic and inorganic opportunities.

Torreya, a global advisory firm serving the life sciences industry today released a report comparing the global pharmaceutical industry in 2020 with the industry in 2015. A key finding is that small companies are playing an outsized role in the sector's growth. According to the report, the top eighteen companies comprised three quarters of the industry in 2015, but in 2020 that percentage has dropped to less than half.

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the acquisition of CerSci Therapeutics, a clinical-stage biotechnology company with worldwide rights to a portfolio of novel compounds for neurological conditions, including non-opioid therapies for acute and chronic pain. Under the terms of the agreement, ACADIA acquired all of the outstanding shares of CerSci for $52.5 million, primarily in ACADIA stock. The transaction closed on August 24, 2020. CerSci shareholders may also receive up to $887 million in development, commercialization, and sales milestones in addition to tiered royalties in the mid-single digits based on annual net sales.

Neumentum announced updates related to development of its two non-opioid analgesic candidates, NTM-001 and NTM-006.

EDITOR'S NOTE: Expanesthetics is developing a class of non-opiate analgesics toward different indications. Neumentum’s development shows the industry and regulatory progress being made in this space.

The Carlyle Group purchases a significant stake in Piramal Pharma, a newly reorganized group within Piramal Enterprises, one of the world's three largest inhaled anesthesia companies.